Enlivex Therapeutics Ownership 2024 | Who Owns Enlivex Therapeutics Now?
Institutional Ownership
11.13%
Insider Ownership
5.95%
Retail Ownership
82.92%
Institutional Holders
19.00
Enlivex Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 9.08% | 0.03% | 1,700,571 | 1,700,571 | 100.00% | 2,414,811 | Jun 30, 2024 |
| MORGAN STANLEY | 1.31% | - | 244,892 | 172,772 | 239.56% | 347,747 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.38% | 0.00% | 71,689 | 1,800 | 2.58% | 101,798 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.13% | 0.00% | 24,820 | 24,820 | 100.00% | 35,244 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.06% | - | 11,429 | 11,429 | 100.00% | 16,229 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.06% | - | 10,420 | - | - | 14,796 | Jun 30, 2024 |
| WELLS FARGO & COMPANY/MN | 0.05% | - | 9,184 | -809 | -8.10% | 13,041 | Jun 30, 2024 |
| GROUP ONE TRADING, L.P. | 0.03% | - | 5,749 | -1,475 | -20.42% | 8,164,000 | Jun 30, 2024 |
| STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 0.02% | - | 3,000 | - | - | 4,260 | Jun 30, 2024 |
| ACTIVEST WEALTH MANAGEMENT | 0.01% | 0.00% | 1,000 | 1,000 | 100.00% | 1,420 | Jun 30, 2024 |
| SRS CAPITAL ADVISORS, INC. | 0.00% | 0.00% | 615 | 615 | 100.00% | 874 | Jun 30, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | 0.00% | - | 400 | - | - | 568 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.00% | - | 231 | -6,920 | -96.77% | 328 | Jun 30, 2024 |
| RED TORTOISE LLC | 0.00% | 0.00% | 150 | - | - | 213 | Jun 30, 2024 |
| UBS GROUP AG | 0.00% | - | 16 | -3,053 | -99.48% | 23 | Jun 30, 2024 |
| GLOBAL RETIREMENT PARTNERS, LLC | 0.00% | - | 11 | 11 | 100.00% | 16 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | 1 | - | - | 1 | Jun 30, 2024 |
| BARCLAYS PLC | - | - | - | -1,000 | -100.00% | - | Jun 30, 2024 |
| SIMPLEX TRADING, LLC | - | - | - | -18,261 | -100.00% | - | Jun 30, 2024 |
Enlivex Therapeutics's largest institutional shareholder is ARMISTICE CAPITAL, LLC, holding 9.08% of the company's total share outstanding, currently valued at $2.41M. The top 10 institutional shareholders own together 11.12% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 9.08% | 0.03% | 1,700,571 | 1,700,571 | 100.00% | 2,414,811 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.13% | 0.00% | 24,820 | 24,820 | 100.00% | 35,244 | Jun 30, 2024 |
| ACTIVEST WEALTH MANAGEMENT | 0.01% | 0.00% | 1,000 | 1,000 | 100.00% | 1,420 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.38% | 0.00% | 71,689 | 1,800 | 2.58% | 101,798 | Jun 30, 2024 |
| RED TORTOISE LLC | 0.00% | 0.00% | 150 | - | - | 213 | Jun 30, 2024 |
| SRS CAPITAL ADVISORS, INC. | 0.00% | 0.00% | 615 | 615 | 100.00% | 874 | Jun 30, 2024 |
| STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 0.02% | - | 3,000 | - | - | 4,260 | Jun 30, 2024 |
| GROUP ONE TRADING, L.P. | 0.03% | - | 5,749 | -1,475 | -20.42% | 8,164,000 | Jun 30, 2024 |
| MORGAN STANLEY | 1.31% | - | 244,892 | 172,772 | 239.56% | 347,747 | Jun 30, 2024 |
| WELLS FARGO & COMPANY/MN | 0.05% | - | 9,184 | -809 | -8.10% | 13,041 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.06% | - | 11,429 | 11,429 | 100.00% | 16,229 | Jun 30, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | 0.00% | - | 400 | - | - | 568 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.06% | - | 10,420 | - | - | 14,796 | Jun 30, 2024 |
| GLOBAL RETIREMENT PARTNERS, LLC | 0.00% | - | 11 | 11 | 100.00% | 16 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.00% | - | 231 | -6,920 | -96.77% | 328 | Jun 30, 2024 |
| UBS GROUP AG | 0.00% | - | 16 | -3,053 | -99.48% | 23 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | 1 | - | - | 1 | Jun 30, 2024 |
| BARCLAYS PLC | - | - | - | -1,000 | -100.00% | - | Jun 30, 2024 |
| SIMPLEX TRADING, LLC | - | - | - | -18,261 | -100.00% | - | Jun 30, 2024 |
The largest Enlivex Therapeutics shareholder by % of total assets is ARMISTICE CAPITAL, LLC. The company owns 1.70M shares of Enlivex Therapeutics (ENLV), representing 0.03% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 9.08% | 0.03% | 1,700,571 | 1,700,571 | 100.00% | 2,414,811 | Jun 30, 2024 |
| MORGAN STANLEY | 1.31% | - | 244,892 | 172,772 | 239.56% | 347,747 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.13% | 0.00% | 24,820 | 24,820 | 100.00% | 35,244 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.06% | - | 11,429 | 11,429 | 100.00% | 16,229 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.38% | 0.00% | 71,689 | 1,800 | 2.58% | 101,798 | Jun 30, 2024 |
| ACTIVEST WEALTH MANAGEMENT | 0.01% | 0.00% | 1,000 | 1,000 | 100.00% | 1,420 | Jun 30, 2024 |
| SRS CAPITAL ADVISORS, INC. | 0.00% | 0.00% | 615 | 615 | 100.00% | 874 | Jun 30, 2024 |
| GLOBAL RETIREMENT PARTNERS, LLC | 0.00% | - | 11 | 11 | 100.00% | 16 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | 1 | - | - | 1 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.06% | - | 10,420 | - | - | 14,796 | Jun 30, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | 0.00% | - | 400 | - | - | 568 | Jun 30, 2024 |
| STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 0.02% | - | 3,000 | - | - | 4,260 | Jun 30, 2024 |
| RED TORTOISE LLC | 0.00% | 0.00% | 150 | - | - | 213 | Jun 30, 2024 |
| WELLS FARGO & COMPANY/MN | 0.05% | - | 9,184 | -809 | -8.10% | 13,041 | Jun 30, 2024 |
| BARCLAYS PLC | - | - | - | -1,000 | -100.00% | - | Jun 30, 2024 |
| GROUP ONE TRADING, L.P. | 0.03% | - | 5,749 | -1,475 | -20.42% | 8,164,000 | Jun 30, 2024 |
| UBS GROUP AG | 0.00% | - | 16 | -3,053 | -99.48% | 23 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.00% | - | 231 | -6,920 | -96.77% | 328 | Jun 30, 2024 |
| SIMPLEX TRADING, LLC | - | - | - | -18,261 | -100.00% | - | Jun 30, 2024 |
As of Jun 30 2024, Enlivex Therapeutics's largest institutional buyer is ARMISTICE CAPITAL, LLC. The company purchased 1.70M stocks of ENLV, valued at $2.41M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SIMPLEX TRADING, LLC | - | - | - | -18,261 | -100.00% | - | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.00% | - | 231 | -6,920 | -96.77% | 328 | Jun 30, 2024 |
| UBS GROUP AG | 0.00% | - | 16 | -3,053 | -99.48% | 23 | Jun 30, 2024 |
| GROUP ONE TRADING, L.P. | 0.03% | - | 5,749 | -1,475 | -20.42% | 8,164,000 | Jun 30, 2024 |
| BARCLAYS PLC | - | - | - | -1,000 | -100.00% | - | Jun 30, 2024 |
| WELLS FARGO & COMPANY/MN | 0.05% | - | 9,184 | -809 | -8.10% | 13,041 | Jun 30, 2024 |
| RED TORTOISE LLC | 0.00% | 0.00% | 150 | - | - | 213 | Jun 30, 2024 |
| STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 0.02% | - | 3,000 | - | - | 4,260 | Jun 30, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | 0.00% | - | 400 | - | - | 568 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.06% | - | 10,420 | - | - | 14,796 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | 1 | - | - | 1 | Jun 30, 2024 |
| GLOBAL RETIREMENT PARTNERS, LLC | 0.00% | - | 11 | 11 | 100.00% | 16 | Jun 30, 2024 |
| SRS CAPITAL ADVISORS, INC. | 0.00% | 0.00% | 615 | 615 | 100.00% | 874 | Jun 30, 2024 |
| ACTIVEST WEALTH MANAGEMENT | 0.01% | 0.00% | 1,000 | 1,000 | 100.00% | 1,420 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.38% | 0.00% | 71,689 | 1,800 | 2.58% | 101,798 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.06% | - | 11,429 | 11,429 | 100.00% | 16,229 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.13% | 0.00% | 24,820 | 24,820 | 100.00% | 35,244 | Jun 30, 2024 |
| MORGAN STANLEY | 1.31% | - | 244,892 | 172,772 | 239.56% | 347,747 | Jun 30, 2024 |
| ARMISTICE CAPITAL, LLC | 9.08% | 0.03% | 1,700,571 | 1,700,571 | 100.00% | 2,414,811 | Jun 30, 2024 |
As of Jun 30 2024, Enlivex Therapeutics's biggest institutional seller is SIMPLEX TRADING, LLC. The company sold -18.26K shares of ENLV, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 9.08% | 0.03% | 1,700,571 | 1,700,571 | 100.00% | 2,414,811 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.13% | 0.00% | 24,820 | 24,820 | 100.00% | 35,244 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.06% | - | 11,429 | 11,429 | 100.00% | 16,229 | Jun 30, 2024 |
| ACTIVEST WEALTH MANAGEMENT | 0.01% | 0.00% | 1,000 | 1,000 | 100.00% | 1,420 | Jun 30, 2024 |
| SRS CAPITAL ADVISORS, INC. | 0.00% | 0.00% | 615 | 615 | 100.00% | 874 | Jun 30, 2024 |
| GLOBAL RETIREMENT PARTNERS, LLC | 0.00% | - | 11 | 11 | 100.00% | 16 | Jun 30, 2024 |
Enlivex Therapeutics's largest new institutional shareholder by number of shares is ARMISTICE CAPITAL, LLC, purchased 1.70M shares, valued at $2.41M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SIMPLEX TRADING, LLC | - | - | - | -18,261 | -100.00% | - | Jun 30, 2024 |
| BARCLAYS PLC | - | - | - | -1,000 | -100.00% | - | Jun 30, 2024 |
Enlivex Therapeutics's largest sold out institutional shareholder by shares sold is SIMPLEX TRADING, LLC, sold -18.26K shares, valued at -, as of undefined.
Enlivex Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| ETF Series Solutions | 0.00% | 5,160 | - | - | Jan 31, 2024 |
Enlivex Therapeutics's largest mutual fund holder by % of total assets is "ETF Series Solutions", owning 5.16K shares, compromising 0.00% of its total assets.
Enlivex Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 19 | - |
| 31 Mar, 24 | 19 | 5.56% |
| 31 Dec, 23 | 18 | - |
| 30 Sep, 23 | 18 | -14.29% |
| 30 Jun, 23 | 21 | 5.00% |
| 31 Mar, 23 | 20 | -16.67% |
| 31 Dec, 22 | 24 | 9.09% |
| 30 Sep, 22 | 22 | - |
| 30 Jun, 22 | 22 | -4.35% |
| 31 Mar, 22 | 23 | -11.54% |
| 31 Dec, 21 | 26 | - |
| 30 Sep, 21 | 26 | 13.04% |
| 30 Jun, 21 | 23 | -14.81% |
| 31 Mar, 21 | 27 | 92.86% |
| 31 Dec, 20 | 14 | 250.00% |
| 30 Sep, 20 | 4 | -33.33% |
| 30 Jun, 20 | 6 | 20.00% |
| 31 Mar, 20 | 5 | 25.00% |
| 31 Dec, 19 | 4 | - |
| 30 Sep, 19 | 4 | 100.00% |
| 30 Jun, 19 | 2 | 100.00% |
| 31 Mar, 19 | 1 | - |
As of 30 Jun 24, 19 institutions are holding Enlivex Therapeutics's shares, representing an increase of 0.00% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 2,084,178 | 539.03% |
| 31 Mar, 24 | 326,146 | 73.06% |
| 31 Dec, 23 | 188,457 | -23.18% |
| 30 Sep, 23 | 245,309 | -14.64% |
| 30 Jun, 23 | 287,396 | -11.68% |
| 31 Mar, 23 | 325,394 | 2.01% |
| 31 Dec, 22 | 318,973 | 1.80% |
| 30 Sep, 22 | 313,343 | -46.22% |
| 30 Jun, 22 | 582,670 | -29.27% |
| 31 Mar, 22 | 823,799 | 24.34% |
| 31 Dec, 21 | 662,557 | -21.85% |
| 30 Sep, 21 | 847,803 | -14.17% |
| 30 Jun, 21 | 987,814 | -6.78% |
| 31 Mar, 21 | 1,059,657 | 166.01% |
| 31 Dec, 20 | 398,346 | 24.08% |
| 30 Sep, 20 | 321,043 | -4.67% |
| 30 Jun, 20 | 336,757 | -41.33% |
| 31 Mar, 20 | 573,973 | 615.53% |
| 31 Dec, 19 | 80,217 | 58.06% |
| 30 Sep, 19 | 50,751 | 136.82% |
| 30 Jun, 19 | 21,430 | 21.15% |
| 31 Mar, 19 | 17,689 | - |
Enlivex Therapeutics (ENLV) has 2.08M shares outstanding as of 30 Jun 24, up 539.03% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 11.13% | 360.97% |
| 31 Mar, 24 | 1.76% | 170.98% |
| 31 Dec, 23 | 1.01% | 57.74% |
| 30 Sep, 23 | 1.32% | 55.00% |
| 30 Jun, 23 | 1.55% | 49.60% |
| 31 Mar, 23 | 1.77% | 58.83% |
| 31 Dec, 22 | 1.73% | 59.74% |
| 30 Sep, 22 | 1.70% | 16.94% |
| 30 Jun, 22 | 3.17% | 15.77% |
| 31 Mar, 22 | 4.48% | 34.26% |
| 31 Dec, 21 | 3.62% | 16.88% |
| 30 Sep, 21 | 4.63% | 15.90% |
| 30 Jun, 21 | 5.40% | 13.05% |
| 31 Mar, 21 | 6.43% | 73.45% |
| 31 Dec, 20 | 2.96% | 52.04% |
| 30 Sep, 20 | 2.38% | 38.11% |
| 30 Jun, 20 | 2.50% | 5.68% |
| 31 Mar, 20 | 6.64% | 771.54% |
| 31 Dec, 19 | 0.93% | 269.36% |
| 30 Sep, 19 | 0.59% | 955.69% |
| 30 Jun, 19 | 0.25% | 592.42% |
| 31 Mar, 19 | 0.20% | - |
As of 30 Jun 24, Enlivex Therapeutics is held by 11.13% institutional shareholders, representing a 360.97% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 8 | 33.33% |
| 31 Mar, 24 | 6 | -14.29% |
| 31 Dec, 23 | 7 | 133.33% |
| 30 Sep, 23 | 3 | -25.00% |
| 30 Jun, 23 | 4 | - |
| 31 Mar, 23 | 4 | -42.86% |
| 31 Dec, 22 | 7 | -12.50% |
| 30 Sep, 22 | 8 | -11.11% |
| 30 Jun, 22 | 9 | -30.77% |
| 31 Mar, 22 | 13 | 44.44% |
| 31 Dec, 21 | 9 | -25.00% |
| 30 Sep, 21 | 12 | 20.00% |
| 30 Jun, 21 | 10 | -54.55% |
| 31 Mar, 21 | 22 | 120.00% |
| 31 Dec, 20 | 10 | 233.33% |
| 30 Sep, 20 | 3 | -40.00% |
| 30 Jun, 20 | 5 | - |
| 31 Mar, 20 | 5 | 66.67% |
| 31 Dec, 19 | 3 | -25.00% |
| 30 Sep, 19 | 4 | 100.00% |
| 30 Jun, 19 | 2 | 100.00% |
| 31 Mar, 19 | 1 | - |
8 institutional shareholders have increased their position in ENLV stock as of 30 Jun 24 compared to 6 in the previous quarter (a 33.33% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 5 | 150.00% |
| 31 Mar, 24 | 2 | -33.33% |
| 31 Dec, 23 | 3 | -25.00% |
| 30 Sep, 23 | 4 | -42.86% |
| 30 Jun, 23 | 7 | 16.67% |
| 31 Mar, 23 | 6 | -14.29% |
| 31 Dec, 22 | 7 | 133.33% |
| 30 Sep, 22 | 3 | -40.00% |
| 30 Jun, 22 | 5 | 66.67% |
| 31 Mar, 22 | 3 | -75.00% |
| 31 Dec, 21 | 12 | 71.43% |
| 30 Sep, 21 | 7 | 16.67% |
| 30 Jun, 21 | 6 | 500.00% |
| 31 Mar, 21 | 1 | - |
| 31 Dec, 20 | 1 | - |
| 30 Sep, 20 | 1 | - |
| 30 Jun, 20 | 1 | - |
| 31 Mar, 20 | - | -100.00% |
| 31 Dec, 19 | 1 | - |
| 30 Sep, 19 | - | - |
| 30 Jun, 19 | - | - |
| 31 Mar, 19 | - | - |
5 institutional shareholders have reduced their position in ENLV stock as of 30 Jun 24 compared to 2 in the previous quarter (a 150.00% increase).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 19 | - | 2,084,178 | 539.03% | 11.13% | 360.97% | 8 | 33.33% | 5 | 150.00% |
| 31 Mar, 24 | 19 | 5.56% | 326,146 | 73.06% | 1.76% | 170.98% | 6 | -14.29% | 2 | -33.33% |
| 31 Dec, 23 | 18 | - | 188,457 | -23.18% | 1.01% | 57.74% | 7 | 133.33% | 3 | -25.00% |
| 30 Sep, 23 | 18 | -14.29% | 245,309 | -14.64% | 1.32% | 55.00% | 3 | -25.00% | 4 | -42.86% |
| 30 Jun, 23 | 21 | 5.00% | 287,396 | -11.68% | 1.55% | 49.60% | 4 | - | 7 | 16.67% |
| 31 Mar, 23 | 20 | -16.67% | 325,394 | 2.01% | 1.77% | 58.83% | 4 | -42.86% | 6 | -14.29% |
| 31 Dec, 22 | 24 | 9.09% | 318,973 | 1.80% | 1.73% | 59.74% | 7 | -12.50% | 7 | 133.33% |
| 30 Sep, 22 | 22 | - | 313,343 | -46.22% | 1.70% | 16.94% | 8 | -11.11% | 3 | -40.00% |
| 30 Jun, 22 | 22 | -4.35% | 582,670 | -29.27% | 3.17% | 15.77% | 9 | -30.77% | 5 | 66.67% |
| 31 Mar, 22 | 23 | -11.54% | 823,799 | 24.34% | 4.48% | 34.26% | 13 | 44.44% | 3 | -75.00% |
| 31 Dec, 21 | 26 | - | 662,557 | -21.85% | 3.62% | 16.88% | 9 | -25.00% | 12 | 71.43% |
| 30 Sep, 21 | 26 | 13.04% | 847,803 | -14.17% | 4.63% | 15.90% | 12 | 20.00% | 7 | 16.67% |
| 30 Jun, 21 | 23 | -14.81% | 987,814 | -6.78% | 5.40% | 13.05% | 10 | -54.55% | 6 | 500.00% |
| 31 Mar, 21 | 27 | 92.86% | 1,059,657 | 166.01% | 6.43% | 73.45% | 22 | 120.00% | 1 | - |
| 31 Dec, 20 | 14 | 250.00% | 398,346 | 24.08% | 2.96% | 52.04% | 10 | 233.33% | 1 | - |
| 30 Sep, 20 | 4 | -33.33% | 321,043 | -4.67% | 2.38% | 38.11% | 3 | -40.00% | 1 | - |
| 30 Jun, 20 | 6 | 20.00% | 336,757 | -41.33% | 2.50% | 5.68% | 5 | - | 1 | - |
| 31 Mar, 20 | 5 | 25.00% | 573,973 | 615.53% | 6.64% | 771.54% | 5 | 66.67% | - | -100.00% |
| 31 Dec, 19 | 4 | - | 80,217 | 58.06% | 0.93% | 269.36% | 3 | -25.00% | 1 | - |
| 30 Sep, 19 | 4 | 100.00% | 50,751 | 136.82% | 0.59% | 955.69% | 4 | 100.00% | - | - |
| 30 Jun, 19 | 2 | 100.00% | 21,430 | 21.15% | 0.25% | 592.42% | 2 | 100.00% | - | - |
| 31 Mar, 19 | 1 | - | 17,689 | - | 0.20% | - | 1 | - | - | - |
Enlivex Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Enlivex Therapeutics's stock was made by Murray Michael Anthony on Oct 27 2015, selling 56,390 shares at $2.78 per share (valued at $156.76K).
Enlivex Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|
Enlivex Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| CKPT | Checkpoint Therapeutics, Inc. |
| PPBT | Purple Biotech Ltd. |
| PMVP | PMV Pharmaceuticals, Inc. |
| ARDS | Aridis Pharmaceuticals, Inc. |
| GMDA | Gamida Cell Ltd. |
| ALDX | Aldeyra Therapeutics, Inc. |
| MRUS | Merus N.V. |
| APVO | Aptevo Therapeutics Inc. |
| HSTO | Histogen Inc. |
| PLUR | Pluri Inc. |
| IPSC | Century Therapeutics, Inc. |
| CLGN | CollPlant Biotechnologies Ltd. |
| PHIO | Phio Pharmaceuticals Corp. |
| BLRX | BioLineRx Ltd. |
| CRVS | Corvus Pharmaceuticals, Inc. |
| KROS | Keros Therapeutics, Inc. |
| VCEL | Vericel Corporation |
ENLV Ownership FAQ
Who Owns Enlivex Therapeutics?
Enlivex Therapeutics is owned by institutional shareholders (11.13%), insiders (5.95%), and public (82.92%). The largest institutional shareholder of Enlivex Therapeutics is ARMISTICE CAPITAL, LLC (9.08% of total shares) and the top mutual fund owner is ETF Series Solutions (0.00% of total shares).
Who are the major institutional shareholders of Enlivex Therapeutics?
Enlivex Therapeutics's major institutional shareholders are ARMISTICE CAPITAL, LLC, MORGAN STANLEY, RENAISSANCE TECHNOLOGIES LLC, XTX TOPCO LTD, and GOLDMAN SACHS GROUP INC. The top five shareholders own together 10.96% of the company's share outstanding.
How many Enlivex Therapeutics shareholders are there?
As of Jun 2024, there are 19 institutional shareholders of Enlivex Therapeutics.
What percentage of Enlivex Therapeutics is owned by ARMISTICE CAPITAL, LLC?
ARMISTICE CAPITAL, LLC owns 1.7M shares of Enlivex Therapeutics, representing 9.08% of the company's total shares outstanding, valued at $2.41M (as of Jun 2024).
What percentage of Enlivex Therapeutics is owned by MORGAN STANLEY?
As of Jun 2024, MORGAN STANLEY holds 244.89K shares of Enlivex Therapeutics (ENLV), compromising 1.31% of the company, valued at $347.75K.
What percentage of Enlivex Therapeutics is owned by RENAISSANCE TECHNOLOGIES LLC?
RENAISSANCE TECHNOLOGIES LLC is the third largest holder of Enlivex Therapeutics. The company owns 71.69K of the company's shares outstanding (worth $101.8K).